Biotech | February 23, 2026
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
The data highlights its RSV vaccine cuts hospitalizations in older adults
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Subscribe To Our Newsletter & Stay Updated
